Biliary Tract Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Biliary Tract Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 3 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR) | Phase 2 | Active, not recruiting | 2026-10-27 | in 68 d | 2026-07-02 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | 2026-11-17 | in 89 d | 2026-07-29 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CMPX | Compass Therapeutics | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Best Overall Response | Phase 2/3 | Active, not recruiting | 2026-12-01 | in 103 d | 2026-05-07 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Biliary Tract Cancer
most recently updated first40 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerNCT06467357Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig | Phase 3 | Recruiting | Drug: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig | Biliary Tract Cancer | 620 | 2024-08-12 | 2028-06-12 | in 662 d | 2026-08-19 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | 460 | 2021-10-18 | 2027-09-29 | in 405 d | 2026-08-12 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| AZN | AstraZeneca | — | Study for AZD4360 in Participants With Advanced Solid TumoursNCT06921928Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360 | Phase 1/2 | Active, not recruiting | Drug: AZD4360 | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 31 | 2025-04-29 | 2027-03-31 | in 223 d | 2026-07-31 |
| AZN | AstraZeneca | — | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)NCT05771480Number of participants with Grade 3 or 4 possibly related adverse event (PRAE) | Phase 3 | Active, not recruiting | Biological: Durvalumab · Drug: Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel | Biliary Tract Cancer | 142 | 2023-08-16 | 2025-10-02actual | — | 2026-07-29 |
| AZN | AstraZeneca | — | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | Drug: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 226 | 2023-12-13 | 2026-11-17 | in 89 d | 2026-07-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerNCT02711553results2021-02-26Progression Free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV | Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer | 309 | 2016-05-19 | 2018-02-16actual | — | 2026-07-22 |
| AZN | AstraZeneca | — | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)NCT07221253Overall Survival (OS) in the PDL1 ≥ 1% population | Phase 3 | Recruiting | Drug: Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin | Biliary Tract Cancer | 1,100 | 2025-12-04 | 2029-07-31 | in 1,076 d | 2026-07-20 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors | Phase 3 | Recruiting | Drug: Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab | Biliary Tract Cancer | 286 | 2024-07-19 | 2028-12-01 | in 834 d | 2026-07-14 |
| AZN | AstraZeneca | — | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)NCT06109779Recurrence free survival (RFS) for Arm A vs. Arm B | Phase 3 | Active, not recruiting | Drug: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil] | Biliary Tract Cancer | 760 | 2023-12-04 | 2029-01-02 | in 866 d | 2026-07-10 |
| AZN | AstraZeneca | — | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR) | Phase 2 | Active, not recruiting | Drug: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin | Hepatocellular Carcinoma, Biliary Tract Cancer | 294 | 2023-04-24 | 2026-10-27 | in 68 d | 2026-07-02 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy | Phase 1/2 | Active, not recruiting | Drug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms | 540 | 2021-07-19 | Apr 2027 | ≤ 253 d | 2026-05-29 |
| AZN | AstraZeneca | — | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)NCT03875235results2023-04-13Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Durvalumab, Placebo | Biliary Tract Neoplasms | 810 | 2019-04-16 | 2021-08-11actual | — | 2026-05-26 |
| LSTA | Lisata Therapeutics, Inc. | $10M | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356results2026-05-26Number of Subjects Experiencing Any Adverse Event | Phase 2 | Terminatedsponsor's stated reason: The study was halted prematurely to allow analysis of the results. | Drug: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 66 | 2023-05-13 | 2026-04-05actual | — | 2026-05-26 |
| CMPX | Compass Therapeutics | $430M | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Best Overall Response | Phase 2/3 | Active, not recruiting | Drug: CTX-009, Paclitaxel | Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer | 168 | 2023-01-09 | 2026-12-01 | in 103 d | 2026-05-07 |
| AZN | AstraZeneca | — | A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC PatientsNCT07101874observationalTime to treatment failure (TTF) | — | Completed | — | Biliary Tract Cancer | 729 | 2025-08-22 | 2026-02-28actual | — | 2026-04-17 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| REPL | Replimune, Inc. | $1.5B | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598Overall Response Rate per modified RECIST 1.1 | Phase 2 | Recruiting | Biological: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy | Hepatocellular Carcinoma, Biliary Tract Cancer | 60 | 2024-08-01 | 2027-12-01 | in 468 d | 2026-04-02 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyNCT06793709observationalNumber of Participants With Adverse Drug Reactions | — | Recruiting | Other: No Intervention | Biliary Tract Cancer | 60 | 2025-07-10 | 2032-11-20 | in 2,284 d | 2026-02-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersNCT04430738results2025-09-09Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 40 | 2020-09-15 | 2024-07-31actual | — | 2026-02-24 |
| AZN | AstraZeneca | — | Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEINCT05835778observationalIncidence of ADRs | — | Completed | — | Biliary Tract Cancer | 236 | 2023-06-06 | 2025-11-21actual | — | 2026-01-14 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380results2024-11-13Confirmed Objective Response Rate (cORR) as Assessed by Investigator | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, fulvestrant | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | 217 | 2021-01-11 | 2023-11-01actual | — | 2025-12-19 |
| NXTC | NextCure, Inc. | $30M | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Drug: LNCB74 | Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors | 145 | 2025-01-07 | Dec 2026 | ≤ 133 d | 2025-12-16 |
| ELTX | Elicio Therapeutics | $82M | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsNCT04853017results2025-01-17The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 | Phase 1 | Completed | Drug: ELI-002 2P | Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma | 25 | 2021-10-04 | 2023-01-26actual | — | 2025-09-05 |
| AZN | AstraZeneca | — | A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)NCT05924880The incidence of Possible related adverse events(PRAE) Grade 3 or 4 | Phase 3 | Completed | Drug: durvalumab | Biliary Tract Cancers | 116 | 2023-07-21 | 2025-02-07actual | — | 2025-04-22 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsNCT04683939results2024-10-02Occurrence of Treatment-emergent Adverse Events (TEAEs) Within a Patient Including Grade ≥ 3, Serious, Fatal TEAE by Relationship | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT141, Nab-paclitaxel, Gemcitabine | Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer | 13 | 2022-01-18 | 2023-07-24actual | — | 2024-10-02 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerNCT02443324results2024-07-31Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Ramucirumab, Pembrolizumab | Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer | 175 | 2015-07-29 | 2018-08-31actual | — | 2024-07-31 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyNCT02579616results2020-12-23Objective Response Rate (ORR) | Phase 2 | Completed | Drug: Lenvatinib | Biliary Tract Cancer | 29 | 2015-10-23 | 2016-11-22actual | — | 2020-12-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerNCT03027284Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Merestinib, Cisplatin, Gemcitabine | Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma, Gall Bladder Carcinoma, Solid Tumor, Non-Hodgkin's Lymphoma | 19 | 2017-02-03 | 2019-06-20actual | — | 2020-05-19 |
| AZN | AstraZeneca | — | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursNCT02586987Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events | Phase 1 | Completed | Drug: Selumetinib, MEDI4736, Tremelimumab | Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer | 58 | 2015-12-28 | 2018-07-25actual | — | 2019-11-18 |
| GALT | Galectin Therapeutics Inc. | $355M | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerNCT00386516Objective response rate (ORR) defined as complete response (CR) rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST) | Phase 2 | Withdrawnsponsor's stated reason: Financing and re-organization | Drug: GM-CT-01, 5-Fluorouracil | Cancer of the Bile Duct, Gallbladder Cancer | 0 | Sep 2006 | Jun 2009actual | — | 2017-08-01 |
| 4568.T | Daiichi Sankyo | $31.7B | DX-8951f in Treating Patients With Biliary CancerNCT00005938 | Phase 2 | Completed | Drug: exatecan mesylate | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer | — | Mar 2000 | Apr 2005actual | — | 2012-05-16 |
| SNY | Sanofi | — | EXIBIT: Oxaliplatin in Biliary Tract CancerNCT00174564To evaluate response rate according to RECIST criteria | Phase 2 | Completed | Drug: oxaliplatin | Biliary Tract Neoplasms | 67 | Apr 2003 | Sep 2006actual | — | 2012-02-17 |
| MNKD | Mannkind Corporation | $1.3B | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.NCT00423254To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP | Phase 1 | Completed | Biological: PSMA/PRAME, PSMA/PRAME | Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary | 12 | Feb 2007 | Sep 2009actual | — | 2010-08-03 |
| LLY | Eli Lilly and Company | $1.15T | Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract CancerNCT00380588results2009-11-19Percentage of Patients Alive at 1 Year (1-Year Survival Rate) | Phase 2 | Completed | Drug: gemcitabine, cisplatin | Biliary Tract Cancer | 84 | Sep 2006 | Oct 2008actual | — | 2009-11-20 |
| LLY | Eli Lilly and Company | $1.15T | Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract CarcinomasNCT00490399To evaluate the response rate | Phase 2 | Completed | Drug: gemcitabine, cisplatin | Biliary Tract Carcinoma | 39 | Mar 2003 | — | — | 2007-06-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Biliary Tract Cancer is matched — 6 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Biliary Tract Cancer
- Biliary Tract Neoplasms
- Biliary Tract Carcinoma
- Gallbladder Cancer
- Gallbladder Carcinoma
- Biliary Tract Cancers
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Biliary Tract Cancer” (a text search, wider than this page)